Market Intelligence, Emerging Biology, and High-Purity Reagents for Mechanotransduction & Adhesion Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VCL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Vinculin Full-Length Recombinant Protein; High purity (>95%), Human origin, Sequence Verified, Theoretical MW 117 kDa. | View Vinculin Products |
| Domain Specific | Vinculin Head Domain (Vh, aa 1-840) and Tail Domain (Vt, aa 881-1066); Isolated domains for PPI mapping. Endotoxin <1EU/ug. | View Vinculin Products |
| Constitutive Mutant | Vinculin T12 (A50I, P264S, L277A, E630K) — high-affinity mutant for adhesion studies; Sequence Verified. | View Vinculin Products |
| Mutant Panel | VCL mutant recombinant proteins (auto-inhibited and open conformations, including clinical variants L277M, M94I) — theoretical MW confirmed, endotoxin controlled. | View VCL Products |
| Gene Delivery | VCL Promise-ORF / Lentivirus — full-length ORF for stable cell line construction and mechanotransduction studies. | View Vinculin Products |
| Benchmark Ab | Anti-VCL Monoclonal Antibody (Research Grade) — recombinant positive control for WB/IF/IP, suitable for mechanotransduction readouts. | View VCL Products |
| Validator | VCL siRNA Set — for knockdown verification and specificity checks in cell adhesion assays. | View VCL Products |
| Binding Partner | Talin-1 (TLN1) Full-Length Protein — direct VCL binding partner for SPR/BLI assays. | View Talin-1 Products |
| Pathway Partner | Paxillin (PXN) Recombinant Protein — focal adhesion scaffold protein, co-regulates cell migration with VCL. | View Paxillin Products |
| Upstream Kinase | FAK (PTK2) Active Kinase Domain — for phosphorylation cascade studies and VCL recruitment. | View FAK Products |
| Related Target | Beta-Catenin (CTNNB1) — adherens junction crosstalk, alternative adhesion node for combo studies. | View CTNNB1 Products |
Critical Assay Challenges Solved by TarMart
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Head-Tail Autoinhibition Disruption | Isolated Vh (1-840) and Vt (881-1066) domains with verified purity >95% for conformational assays. |
| Talin-Vinculin PPI Quantification | Full-length Talin-1 and Vinculin proteins for SPR/BLI binding kinetics (Sequence Verified, correct folding). |
| Cell Migration / Adhesion Assays | Lentivirus particles for stable VCL knockdown/overexpression in fibroblast lines. |
| Mechanotransduction Studies | Mutant Vinculin T12 (constitutively active) and wild-type for comparative functional assays. |
| Conformation-specific PPI Screening (Auto-inhibited vs Open) | Purified VCL Head, Tail, and full-length mutants with confirmed theoretical MW for SPR/ITC. |
| Intracellular Target Engagement Validation | Lentivirus-based stable reporter cell lines for high-content imaging. |
| Cardiomyopathy Mutant Screening | Clinical variant proteins (e.g., L277M, M94I) available, sequence verified by mass spectrometry. |
| Cross-species Translation (Rodent/NHP Fibrosis Models) | Human/Mouse/Cyno VCL ortholog proteins with >95% sequence homology coverage. |
| Off-Target Phenotypic Effects | Validated siRNA included for specificity checks and rescue experiments. |
| Lack of Reliable Pathway Controls | Clinical benchmark recombinant antibodies included for precise Western Blot / IHC readouts. |
Live VCL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Key Clinical Variants in VCL
Based on UniProt P18206 and dbSNP, several disease-associated variants in VCL are documented:
- rs71579353 (CMH15; L277M): Linked to hypertrophic cardiomyopathy 15. This missense mutation alters the tail domain and affects vinculin autoinhibition.
- rs17853882: A variant (likely M94I) associated with altered mechanical stability.
- rs16931179: Another missense variant with potential impact on focal adhesion function.
These variants are critical for studying cardiomyopathy and designing mutant-specific assays. TarMart offers recombinant proteins corresponding to these clinical mutations (L277M, M94I) for screening and validation.
Global Clinical Landscape & Future Outlook
The race for targeting mechanotransduction machinery is intensifying. While VCL functions primarily as an intracellular scaffold, its modulation is heavily implicated in tumor metastasis, cardiovascular disease, and fibrotic disorders. First-generation integrin and FAK inhibitors are reaching the clinic, and the next wave leverages VCL as a pharmacodynamic biomarker and explores allosteric modulators of the VCL-Talin interaction. The demand for high-fidelity VCL reagents—particularly constitutive mutants and isolated domains for PPI disruption screening—is intensifying. Next-generation assays require proteins that accurately replicate the mechanical switching behavior of this critical cytoskeletal component.
Competitive Modality & Indication Snapshot
| Modality | Research Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Allosteric modulators of Vh-Talin binding | Solid Tumors (Metastasis), Desmoplastic Cancers, Fibrosis | Isolated Head Domain + Talin Head for high-throughput screening; need WT & mutant recombinant proteins. |
| Peptide Disruptors / Stapled Peptides | Vinculin-binding peptides derived from Talin | Fibrosis, Cardiovascular | Full-length Vinculin for competitive binding assays; conformational PPI assay. |
| Genetic Approaches (RNAi / siRNA) | CRISPR modulation of VCL expression | Oncology, Cardiac Remodeling, Mechanobiology | Knockdown validation (need high-specificity siRNA). |
| Lentiviral Gene Modulation | Stable VCL overexpression or knockdown | Functional Genomics, Adhesion Research | Stable line construction (need ORF Lentivirus). |
| Gene Therapy / ASO | Mutant correction in cardiomyopathies | Hypertrophic Cardiomyopathy | Phenotypic rescue (need Lentivirus for stable cell line modeling). |
| Targeted Protein Degradation (PROTAC) | Degradation of focal adhesion complex | Advanced Fibrosis / Cancer | Degradation readout (need benchmark antibodies & HEK293 expressed targets). |
| Biophysical Probes | FRET/Force biosensors | Basic Research | Mutant Vinculin T12 as positive control for adhesion strength. |
| Biomarker Assays | Mechanotransduction panel | Refractory Cancers | Selectivity assay (need precisely quantified antigen controls). |